Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | SMYD2 | Q9NRG4 | 3/20 | 0.39 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.34 |
| ▸ | ABL1 | P00519 | 1/20 | 0.32 |
| ▸ | HTR2A | P28223 | 3/20 | 0.31 |
| ▸ | HTR2C | P28335 | 3/20 | 0.31 |
| ▸ | HTR2B | P41595 | 3/20 | 0.31 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.30 |
| ▸ | MAOB | P27338 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18730056 | 1.00 | CYP3A4 (0.41) | CYP3A4HTTSMN1; SMN2SMYD2GRM2 | |
| SCHEMBL10188799 | 0.81 | SLC6A2 (0.41) | CYP3A4HTTSMN1; SMN2SMYD2HTR2C | |
| SCHEMBL30158926 | 0.81 | CYP3A4 (0.41) | CYP3A4HTTSMN1; SMN2SMYD2HTR2A | |
| SCHEMBL30158890 | 0.81 | SMYD2 (0.39) | CYP3A4HTTSMN1; SMN2SMYD2HTR2A | |
| SCHEMBL30159212 | 0.81 | SMYD2 (0.39) | CYP3A4HTTSMN1; SMN2SMYD2HTR2A | |
| SCHEMBL18632298 | 0.81 | SMYD2 (0.39) | CYP3A4HTTSMN1; SMN2SMYD2HTR2A | |
| SCHEMBL17959779 | 0.81 | SMYD2 (0.39) | CYP3A4HTTSMN1; SMN2SMYD2HTR2A | |
| SCHEMBL30159129 | 0.81 | SMYD2 (0.39) | CYP3A4HTTSMN1; SMN2SMYD2HTR2A | |
| SCHEMBL19689355 | 0.81 | CYP3A4 (0.41) | CYP3A4HTTSMN1; SMN2SMYD2HTR2A | |
| SCHEMBL19689354 | 0.81 | CYP3A4 (0.41) | CYP3A4HTTSMN1; SMN2SMYD2HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10441576-B2 | Substituted 1,2-dihydro-3H pyrrolo[1,2-c]imidazol-3 one antibacterials | IDORSIA PHARMACEUTICALS LTD. (CH) | 2019-10-15 | — | — | US | disclosed |
| EP-3334737-B1 | SUBSTITUTED 1,2-DIHYDRO-3H-PYRROLO[1,2-C]IMIDAZOL-3-ONE ANTIBACTERIAL COMPOUNDS | IDORSIA PHARMACEUTICALS LTD (CH) | 2019-10-09 | — | — | EP | disclosed |
| EP-3221300-B1 | ANTIBACTERIAL BENZOTHIAZOLE DERIVATIVES | IDORSIA PHARMACEUTICALS LTD (CH) | 2019-03-20 | — | — | EP | disclosed |
| US-20190031676-A1 | ANTIBACTERIAL ANNULATED PYRROLIDIN-2-ONE DERIVATIVES | IDORSIA PHARMACEUTICALS LTD (CH) | 2019-01-31 | — | — | US | disclosed |
| EP-3114126-B1 | 1,2-DIHYDRO-3H-PYRROLO[1,2-C]IMIDAZOL-3-ONE DERIVATIVES AND THEIR USE AS ANTIBACTERIAL AGENTS | IDORSIA PHARMACEUTICALS LTD (CH) | 2018-10-31 | — | — | EP | disclosed |
| US-10106544-B2 | 1,2-dihydro-3H-pyrrolo[1,2-C]imidazol-3-one derivatives and their use as antibacterial agents | IDORSIA PHARMACEUTICALS LTD (CH) | 2018-10-23 | — | — | US | disclosed |
| US-20180235938-A1 | SUBSTITUTED 1,2-DIHYDRO-3H PYRROLO[1,2-c]IMIDAZOL-3 ONE ANTIBACTERIALS | IDORSIA PHARMACEUTICALS LTD. (CH) | 2018-08-23 | — | — | US | disclosed |
| EP-3143007-B1 | ANTIBACTERIAL QUINAZOLINE-4(3H)-ONE DERIVATIVES | IDORSIA PHARMACEUTICALS LTD (CH) | 2018-07-11 | — | — | EP | disclosed |
| US-20170355687-A1 | ANTIBACTERIAL BENZOTHIAZOLE DERIVATIVES | IDORSIA PHARMACEUTICALS LTD (CH) | 2017-12-14 | — | — | US | disclosed |
| US-9796686-B2 | Antibacterial quinazoline-4(3H)-one derivatives | IDORSIA PHARMACEUTICALS LTD (CH) | 2017-10-24 | — | — | US | disclosed |
| US-20170107223-A1 | 1,2-DIHYDRO-3H-PYRROLO[1,2-C]IMIDAZOL-3-ONE DERIVATIVES AND THEIR USE AS ANTIBACTERIAL AGENTS | IDORSIA PHARMACEUTICALS LTD (CH) | 2017-04-20 | — | — | US | disclosed |
| US-20170081292-A1 | ANTIBACTERIAL QUINAZOLINE-4(3H)-ONE DERIVATIVES | IDORSIA PHARMACEUTICALS LTD (CH) | 2017-03-23 | — | — | US | disclosed |
| EP-3044211-A1 | ANTIBACTERIAL 2H-INDAZOLE DERIVATIVES | Actelion Pharmaceuticals Ltd (CH) | 2016-07-20 | — | — | EP | disclosed |
| WO-2015036964-A1 | ANTIBACTERIAL 2H-INDAZOLE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2015-03-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170081292-A1 | ANTIBACTERIAL QUINAZOLINE-4(3H)-ONE DERIVATIVES | MRPL21, PYM1, MDK | CYP3A4 591/4885HTT 1854/4885SMN1; SMN2 4628/4885 |
| US-20180235938-A1 | SUBSTITUTED 1,2-DIHYDRO-3H PYRROLO[1,2-c]IMIDAZOL-3 ONE ANTIBACTERIALS | CTSH, MRPL21, CASP3 | CYP3A4 805/4885HTT 3689/4885SMN1; SMN2 1933/4885 |
| US-10106544-B2 | 1,2-dihydro-3H-pyrrolo[1,2-C]imidazol-3-one derivatives and their use as antibacterial agents | CCNI, H1-0, H1-3 | CYP3A4 2381/4885HTT 2581/4885SMN1; SMN2 2848/4885 |
| US-20190031676-A1 | ANTIBACTERIAL ANNULATED PYRROLIDIN-2-ONE DERIVATIVES | PYCR1, PSPH, RPSA | CYP3A4 3357/4885HTT 4041/4885SMN1; SMN2 2118/4885 |
| US-10441576-B2 | Substituted 1,2-dihydro-3H pyrrolo[1,2-c]imidazol-3 one antibacterials | CTSH, MRPL21, CASP3 | CYP3A4 805/4885HTT 3689/4885SMN1; SMN2 1933/4885 |
| US-20170107223-A1 | 1,2-DIHYDRO-3H-PYRROLO[1,2-C]IMIDAZOL-3-ONE DERIVATIVES AND THEIR USE AS ANTIBACTERIAL AGENTS | CCNI, H1-0, H1-3 | CYP3A4 2381/4885HTT 2581/4885SMN1; SMN2 2848/4885 |
| US-20170355687-A1 | ANTIBACTERIAL BENZOTHIAZOLE DERIVATIVES | CYP8B1, TUBB, DRD3 | CYP3A4 1095/4885HTT 853/4885SMN1; SMN2 4863/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.